BioStem Technologies GAAP EPS of $0.94 beats by $0.60, revenue of $102.87M beats by $16.19M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2025
0mins
Source: SeekingAlpha
Financial Performance: BioStem Technologies reported a preliminary GAAP EPS of $0.94 for Q4, exceeding expectations by $0.60, while net revenue was $102.87M, down 10.9% year-over-year but beating estimates by $16.19M.
Company Focus: The company is concentrating on advancing wound care solutions, as highlighted in their recent press release and Seeking Alpha's Quant Rating.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
